Venturi Wealth Management LLC Invests $46,000 in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Venturi Wealth Management LLC purchased a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 6,150 shares of the biotechnology company’s stock, valued at approximately $46,000.

Several other institutional investors also recently added to or reduced their stakes in BCRX. Creative Planning increased its stake in shares of BioCryst Pharmaceuticals by 5.9% in the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock worth $375,000 after purchasing an additional 2,734 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,322 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in BioCryst Pharmaceuticals by 44.5% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 17,344 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 5,340 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in BioCryst Pharmaceuticals by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,791 shares of the biotechnology company’s stock valued at $302,000 after buying an additional 15,544 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its holdings in BioCryst Pharmaceuticals by 4.0% during the 3rd quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after acquiring an additional 84,102 shares during the period. Institutional investors own 85.88% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Needham & Company LLC lifted their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Wedbush assumed coverage on BioCryst Pharmaceuticals in a report on Tuesday. They set an “outperform” rating and a $15.00 target price for the company. Barclays upped their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. JMP Securities restated a “market outperform” rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $11.00 target price (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ BCRX opened at $8.28 on Wednesday. The firm’s 50-day moving average price is $8.05 and its 200-day moving average price is $7.85. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $9.50. The company has a market cap of $1.72 billion, a PE ratio of -13.57 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to the consensus estimate of $126.64 million. The company’s revenue was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.28 EPS. As a group, equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.